Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive Effects of Treatment Schemes in Idiopathic Membranous Nephropathy
NCT06245707Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of rituximab in idiopathic membranous nephropathy (IMN) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Montreal Cognitive Assessment at 1 year. Status: unknown.
02
Drugs
rituximab
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT06245707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245707.